T1	PROC 44 95	Estudio de mantenimiento de la eficacia y seguridad
T2	DISO 114 130	colitis ulcerosa
#1	AnnotatorNotes T2	C0009324; Ulcerative Colitis; Disease or Syndrome
T3	CHEM 99 110	mirikizumab
#2	AnnotatorNotes T3	C5139904; mirikizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	PROC 152 275	Estudio de mantenimiento en fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo
T5	DISO 311 327	colitis ulcerosa
#3	AnnotatorNotes T5	C0009324; Ulcerative Colitis; Disease or Syndrome
T6	PROC 1892 1927	interrupción permanente del fármaco
#4	AnnotatorNotes T6	C0850893; stop medication; Therapeutic or Preventive Procedure (?)
T7	DISO 378 394	Colitis ulcerosa
#5	AnnotatorNotes T7	C0009324; Ulcerative Colitis; Disease or Syndrome
T8	DISO 420 436	Colitis ulcerosa
#6	AnnotatorNotes T8	C0009324; Ulcerative Colitis; Disease or Syndrome
T9	CHEM 559 566	fármaco
#7	AnnotatorNotes T9	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T10	CHEM 615 622	fármaco
#8	AnnotatorNotes T10	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T11	PROC 659 669	endoscopia
#9	AnnotatorNotes T11	C0014245; Endoscopy (procedure); Diagnostic Procedure
T12	PROC 744 756	evaluaciones
#10	AnnotatorNotes T12	C1261322; Evaluation procedure; Health Care Activity
T13	PROC 795 805	endoscopia
#11	AnnotatorNotes T13	C0014245; Endoscopy (procedure); Diagnostic Procedure
T14	PROC 893 916	métodos anticonceptivos
#12	AnnotatorNotes T14	C0700589; Contraceptive methods; Therapeutic or Preventive Procedure
T15	PROC 965 976	diagnóstico
#13	AnnotatorNotes T15	C0011900; Diagnosis; Diagnostic Procedure
T16	DISO 980 999	enfermedad de Crohn
#14	AnnotatorNotes T16	C0010346; Crohn Disease; Disease or Syndrome
T17	DISO 1002 1051	enfermedad inflamatoria intestinal no clasificada
#15	AnnotatorNotes T17	C4268603; Colonic inflammatory bowel disease unclassified; Disease or Syndrome
T18	DISO 1053 1074	colitis indeterminada
#16	AnnotatorNotes T18	C0341332; Indeterminate colitis; Disease or Syndrome
T19	PROC 1139 1163	extirpación de intestino
T20	PROC 1171 1178	cirugía
#17	AnnotatorNotes T20	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T21	PROC 1187 1198	tratamiento
#18	AnnotatorNotes T21	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T22	DISO 1205 1207	CU
#19	AnnotatorNotes T22	C0009324; Ulcerative Colitis; Disease or Syndrome
T23	PROC 1219 1239	estudio de inducción
T24	PROC 1284 1291	cirugía
#20	AnnotatorNotes T24	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T25	PROC 1300 1311	tratamiento
#21	AnnotatorNotes T25	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T26	DISO 1318 1320	CU
#22	AnnotatorNotes T26	C0009324; Ulcerative Colitis; Disease or Syndrome
T27	DISO 1379 1397	displasia colónica
T28	PROC 1422 1435	diagnosticado
#23	AnnotatorNotes T28	C0011900; Diagnosis; Diagnostic Procedure
T29	DISO 1436 1471	cáncer del sistema gastrointestinal
T30	PROC 1531 1542	diagnosticó
#24	AnnotatorNotes T30	C0011900; Diagnosis; Diagnostic Procedure
T31	DISO 1547 1556	infección
#25	AnnotatorNotes T31	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T32	DISO 1574 1585	hepatitis B
#26	AnnotatorNotes T32	C0019163; Hepatitis B; Disease or Syndrome
T33	DISO 1587 1598	hepatitis C
#27	AnnotatorNotes T33	C0019196; Hepatitis C; Disease or Syndrome
T34	DISO 1604 1608	SIDA
#28	AnnotatorNotes T34	C0001175; Acquired Immunodeficiency Syndrome; Disease or Syndrome
T35	DISO 1611 1623	tuberculosis
#29	AnnotatorNotes T35	C0041296; Tuberculosis; Disease or Syndrome
T36	DISO 1625 1627	TB
#30	AnnotatorNotes T36	C0041296; Tuberculosis; Disease or Syndrome
T37	PROC 1661 1681	estudio de inducción
T38	CHEM 1729 1739	medicación
#31	AnnotatorNotes T38	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T39	PROC 1761 1781	estudio de inducción
T40	CHEM 1920 1927	fármaco
#32	AnnotatorNotes T40	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T41	CHEM 282 293	mirikizumab
#33	AnnotatorNotes T41	C5139904; mirikizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T42	PROC 540 566	administración del fármaco
#34	AnnotatorNotes T42	C3469597; Administration of medication; Therapeutic or Preventive Procedure
T43	ANAT 1026 1036	intestinal
#35	AnnotatorNotes T43	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T44	ANAT 1154 1163	intestino
#36	AnnotatorNotes T44	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T45	PROC 1087 1107	estudio de inducción
T46	ANAT 1389 1397	colónica
#37	AnnotatorNotes T46	C0009368; Colon structure; Body Part, Organ, or Organ Component | C1281569; Entire colon; Body Part, Organ, or Organ Component
T47	ANAT 1447 1471	sistema gastrointestinal
T48	DISO 1600 1603	VIH
#38	AnnotatorNotes T48	C0458074; Human immunodeficiency virus (HIV) status; Finding
T49	Date 12 16	2017
T50	LIVB 297 306	pacientes
#39	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	Neg_cue 580 583	sin
T52	Frequency 824 831	diarias
T53	PROC 838 844	diario
#40	AnnotatorNotes T53	C2216446; maintain symptom diary; Health Care Activity (?)
T55	LIVB 855 860	mujer
#41	AnnotatorNotes T55	C0043210; Woman; Population Group
T57	Spec_cue 1261 1269	probable
T58	Spec_cue 1367 1378	indicios de
T59	Date 686 695	semana 12
T60	LIVB 947 960	Participantes
#42	AnnotatorNotes T60	C4554048; Study Participant; Population Group
T61	LIVB 1117 1130	Participantes
#43	AnnotatorNotes T61	C4554048; Study Participant; Population Group
T62	LIVB 1349 1362	Participantes
#44	AnnotatorNotes T62	C4554048; Study Participant; Population Group
T63	LIVB 1500 1513	Participantes
#45	AnnotatorNotes T63	C4554048; Study Participant; Population Group
T64	LIVB 1691 1704	Participantes
#46	AnnotatorNotes T64	C4554048; Study Participant; Population Group
T65	LIVB 1791 1804	Participantes
#47	AnnotatorNotes T65	C4554048; Study Participant; Population Group
T56	PROC 587 599;611 622	finalización del fármaco
#48	AnnotatorNotes T56	C0850893; stop medication; Therapeutic or Preventive Procedure
T54	PROC 676 682	visita
#49	AnnotatorNotes T54	C1512346; Patient Visit; Health Care Activity
T66	Quantifier_or_Qualifier 683 684	5
A2	Assertion T24 Speculated
A3	Assertion T27 Speculated
A4	Assertion T56 Negated
A5	Assertion T38 Contraindicated
A1	Status T11 History_of
A6	Status T19 History_of
A7	Status T20 History_of
A8	Status T23 History_of
A9	Status T37 History_of
A10	Status T39 History_of
A11	Status T45 History_of
#50	AnnotatorNotes T19	C0741614; Bowel resection; Therapeutic or Preventive Procedure 
#53	AnnotatorNotes T27	C1302363; Dysplasia of colon; Disease or Syndrome 
#56	AnnotatorNotes T47	C0017189; Gastrointestinal tract structure; Body System | C4516948; Entire digestive tract; Body System
#57	AnnotatorNotes T29	C0685938; Malignant neoplasm of gastrointestinal tract; Neoplastic Process
T67	Neg_cue 1037 1039	no
T68	Quantifier_or_Qualifier 1040 1051	clasificada
A12	Assertion T68 Negated
#58	AnnotatorNotes T68	C0008902; Classification; Classification
R1	Negation Arg1:T51 Arg2:T56	
T69	Quantifier_or_Qualifier 600 610	anticipada
A13	Assertion T69 Negated
R2	Has_Quantifier_or_Qualifier Arg1:T56 Arg2:T69	
R3	Negation Arg1:T51 Arg2:T69	
R4	Negation Arg1:T67 Arg2:T68	
R5	Speculation Arg1:T57 Arg2:T24	
R6	Speculation Arg1:T58 Arg2:T27	
T70	Spec_cue 1876 1888	necesitarían
A14	Assertion T6 Speculated
R7	Speculation Arg1:T70 Arg2:T6	
R8	Experiences Arg1:T65 Arg2:T6	
T71	Observation 1822 1846	anomalías de laboratorio
R9	Experiences Arg1:T65 Arg2:T71	
R10	Experiences Arg1:T50 Arg2:T41	
R11	Experiences Arg1:T50 Arg2:T5	
T72	Quantifier_or_Qualifier 328 334	activa
#59	AnnotatorNotes T72	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R12	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T72	
T73	Quantifier_or_Qualifier 437 443	activa
#60	AnnotatorNotes T73	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R13	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T73	
T74	Quantifier_or_Qualifier 1629 1635	activa
#61	AnnotatorNotes T74	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R14	Has_Quantifier_or_Qualifier Arg1:T35 Arg2:T74	
R15	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T74	
T75	Quantifier_or_Qualifier 338 354	moderada a grave
#62	AnnotatorNotes T75	C1299393; Moderate to severe; Qualitative Concept
R16	Has_Quantifier_or_Qualifier Arg1:T5 Arg2:T75	
T76	Quantifier_or_Qualifier 447 463	moderada a grave
#63	AnnotatorNotes T76	C1299393; Moderate to severe; Qualitative Concept
R17	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T76	
T77	Observation 497 518	completado el estudio
#64	AnnotatorNotes T77	C2732579; Completion of clinical trial; Finding
T78	Quantifier_or_Qualifier 529 539	al menos 1
R18	Has_Quantifier_or_Qualifier Arg1:T42 Arg2:T78	
R19	Used_for Arg1:T9 Arg2:T42	
R20	Before Arg1:T42 Arg2:T77	
#65	AnnotatorNotes T69	C1279919; Early; Temporal Concept
R21	Used_for Arg1:T10 Arg2:T56	
R22	Overlap Arg1:T11 Arg2:T54	
R23	Before Arg1:T11 Arg2:T77	
R24	Has_Quantifier_or_Qualifier Arg1:T54 Arg2:T66	
R25	Overlap Arg1:T11 Arg2:T59	
R26	Overlap Arg1:T54 Arg2:T59	
T79	Observation 706 715	dispuesto
R28	Has_Frequency Arg1:T53 Arg2:T52	
T80	Quantifier_or_Qualifier 769 780	programadas
#66	AnnotatorNotes T80	C0205539; Scheduled - procedure status; Qualitative Concept
R29	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T80	
#67	AnnotatorNotes T79	C0600109; Willing; Finding (?)
T81	Observation 721 726	capaz
#68	AnnotatorNotes T81	C1299581; Able (finding); Finding (?) | C1555472; Authorized; Finding (?)
R30	Overlap Arg1:T79 Arg2:T12	
R31	Overlap Arg1:T81 Arg2:T12	
R32	Overlap Arg1:T79 Arg2:T13	
R33	Overlap Arg1:T81 Arg2:T13	
R34	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T80	
R35	Overlap Arg1:T79 Arg2:T53	
R36	Overlap Arg1:T81 Arg2:T53	
R37	Has_Quantifier_or_Qualifier Arg1:T53 Arg2:T80	
R38	Experiences Arg1:T55 Arg2:T14	
R39	Experiences Arg1:T60 Arg2:T16	
R40	Experiences Arg1:T60 Arg2:T17	
R41	Location_of Arg1:T43 Arg2:T17	
R42	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T68	
R43	Experiences Arg1:T60 Arg2:T18	
R44	Overlap Arg1:T16 Arg2:T45	
R45	Overlap Arg1:T17 Arg2:T45	
R46	Overlap Arg1:T18 Arg2:T45	
R47	Experiences Arg1:T61 Arg2:T19	
R48	Location_of Arg1:T44 Arg2:T19	
R49	Experiences Arg1:T61 Arg2:T20	
R50	Experiences Arg1:T61 Arg2:T21	
R51	Experiences Arg1:T61 Arg2:T22	
R52	Overlap Arg1:T19 Arg2:T23	
R53	Overlap Arg1:T20 Arg2:T23	
R54	Overlap Arg1:T21 Arg2:T23	
R55	Experiences Arg1:T61 Arg2:T24	
R56	Experiences Arg1:T61 Arg2:T25	
R57	Experiences Arg1:T61 Arg2:T26	
T82	PROC 1332 1339	estudio
#51	AnnotatorNotes T82	C0008976; Clinical Trials; Research Activity
R59	Overlap Arg1:T25 Arg2:T82	
R60	Overlap Arg1:T24 Arg2:T82	
R62	Experiences Arg1:T62 Arg2:T27	
R63	Location_of Arg1:T46 Arg2:T27	
R64	Experiences Arg1:T62 Arg2:T29	
R65	Location_of Arg1:T47 Arg2:T29	
T83	PROC 1483 1490	estudio
#52	AnnotatorNotes T83	C0008976; Clinical Trials; Research Activity
R66	Overlap Arg1:T29 Arg2:T83	
R67	Overlap Arg1:T28 Arg2:T83	
R68	Overlap Arg1:T15 Arg2:T45	
R69	Experiences Arg1:T63 Arg2:T31	
R70	Experiences Arg1:T63 Arg2:T32	
R71	Experiences Arg1:T63 Arg2:T33	
R72	Experiences Arg1:T63 Arg2:T48	
R73	Experiences Arg1:T63 Arg2:T34	
R74	Experiences Arg1:T63 Arg2:T35	
R75	Experiences Arg1:T63 Arg2:T36	
R76	Overlap Arg1:T30 Arg2:T37	
R77	Overlap Arg1:T31 Arg2:T37	
R78	Overlap Arg1:T32 Arg2:T37	
R79	Overlap Arg1:T33 Arg2:T37	
R80	Overlap Arg1:T48 Arg2:T37	
R81	Overlap Arg1:T34 Arg2:T37	
R82	Overlap Arg1:T35 Arg2:T37	
R83	Overlap Arg1:T36 Arg2:T37	
T84	Quantifier_or_Qualifier 1557 1567	importante
#55	AnnotatorNotes T84	C3898777; Important; Qualitative Concept
R84	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T84	
R85	Experiences Arg1:T64 Arg2:T38	
T85	Quantifier_or_Qualifier 1723 1728	nueva
#54	AnnotatorNotes T85	C0205314; New; Qualitative Concept
R86	Has_Quantifier_or_Qualifier Arg1:T38 Arg2:T85	
R87	Overlap Arg1:T38 Arg2:T39	
#69	AnnotatorNotes T71	C3648370; laboratory tests nonspecific abnormal findings; Finding
T86	CONC 1857 1863	inicio
#70	AnnotatorNotes T86	C4684789; Study Start; Temporal Concept | C2349982; Study start time; Temporal Concept
R88	Before Arg1:T71 Arg2:T86	
R89	Before Arg1:T71 Arg2:T6	
R90	Used_for Arg1:T40 Arg2:T6	
R58	Overlap Arg1:T22 Arg2:T23	
R61	Overlap Arg1:T26 Arg2:T82	
#71	AnnotatorNotes T66	C0205451; Five; Quantitative Concept
A15	Assertion T55 Hypothetical
A16	Experiencer T60 Patient
A17	Experiencer T50 Patient
A18	Experiencer T61 Patient
A19	Experiencer T62 Patient
A20	Experiencer T63 Patient
A21	Experiencer T64 Patient
A22	Experiencer T65 Patient
